Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

In particular, the third quarter of the fiscal year also saw record revenue and margins, with the gross margin improving by 1.6 percentage points from 58.7% to 60.3%. The company's UGG and Hoka brands ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, Kamada Ltd (NASDAQ: KMDA), plays an important role in helping address rare ...

Catalyst Pharmaceuticals Inc (CPRX) reports a robust 28.3% revenue increase in Q4 2024, driven by strong product performance ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Collegium Pharmaceutical (COLL – Research Report), ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) yesterday and set a price ...

The S&P 500 (SP500) hit new highs during February trade, but that wasn’t enough to stave off a monthly loss. The benchmark ...

US health officials are reportedly reexamining a $590 million agreement awarded to Moderna (Nasdaq: MRNA) for the development ...

South Korean vaccine maker SK bioscience today revealed that it has received prior notification from the Pan American Health ...